Headquartered in San Diego, CA Fiscal year ends December NASDAQ: DXCM dexcom.com
DexCom, Inc. is a biosensing technology company that develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes and those seeking to track their glucose levels. Founded in 1999, Dexcom has been a pioneer in CGM technology for over 25 years. The company's products include its core Dexcom CGM platform for insulin-using diabetes patients and the Stelo system, which targets type 2 diabetes patients not using insulin and the broader consumer wellness market. Dexcom sells its products through distributor and direct channels in the United States and internationally. The company is actively expanding its addressable market through clinical trials like the CONNECT study, which demonstrated CGM benefits for non-insulin-using type 2 diabetes patients, and through consumer-oriented features such as AI-driven insights and food logging in the Stelo app. Updated
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it…
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise…
Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran’s peace…
Pre-Market Stock Futures: The futures are lower on Tuesday after traders kicked off the holiday-shortened trading week with a massive Monday rally, with all major indices finishing the day higher. A combination…
In the past week or so, renowned investors Carl Icahn and Mario Gabelli led some huge insider buying. These were not the only notable purchases though.
Chase Coleman III is the founder of Tiger Global Management. Coleman’s hedge fund is a whale with nearly $56 billion in assets under management gathered from 42 wealthy clients. As 24/7 Wall…
Will Ashworth It’s time to buy on the dip. The only problem? There aren’t many to choose from. Of the 503 S&P 500 stocks, 229 are currently up more than 20% year-to-date, compared to…
Investors have been on a roller coaster ride for the past four years and the stock market may be heading into another big loop higher. Federal Reserve chairman Jay Powell gave his…
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Carnival, Deere, Delta Air Lines, DexCom, Enovix, First Republic Bank, GitLab, Hartford Financial Services, Interpublic Group, Invesco, Lululemon Athletica, Macy’s, Marathon Petroleum, Medtronic,…
U.S. equities are trading somewhat higher in Tuesday's premarket session as investors wait to hear what Federal Reserve chief Jerome Powell has to say to Congress.
Another cryptocurrency exchange is in hot water, and a little-known penny stock is making a big noise on a merger announcement.
Friday's top analyst upgrades and downgrades included Datadog, DexCom, Exelixis, Lam Research, Las Vegas Sands, Lyft, Match, Nasdaq, Next Era Energy, Norfolk Southern, Pfizer, Walmart and Wolfspeed.
After a horrific year in the markets, Jefferies has made some big changes to its Franchise Picks list of top stocks. These eight outstanding additions to the list have plenty of upside…
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, AES, Amazon.com, CommScope, Emerson Electric, Intel, Leslie’s, Microsoft, Paramount Global, Prologis, Rivian Automotive and Rocket Companies.
DexCom, Inc. is a biosensing technology company that develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes and those seeking to track their glucose levels. Founded in 1999, Dexcom has been a pioneer in CGM technology for over 25 years.
24/7 Wall St.'s 12-month price target for DXCM is $106.25, rated Buy. The Wall Street consensus target is $96.23. DXCM price prediction →
